Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Emerging pharmacotherapies for obesity: A systematic review Pharmacological Reviews Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet When should I consider adding cagrilintide? Cagrilintide is the newest of the weight loss peptides. It works on amylin, which is found in the pancreas. Now, this can be a stand alone product but the GLP 1 physiology in obesity and development of incretin based drugs for chronic weight management Nature Metabolism